COVID-19 novel coronavirus has created a global pandemic. Affected patients may develop acute lung injury and its more severe form – acute respiratory distress syndrome. Hypoxia and severe inflammation increase the production of vascular endothelial growth factor (VEGF), which induces vascular endothelial proliferation. Administration of the anti-VEGF monoclonal antibody bevacizumab is proposed for usage in moderate to severe pneumonia. We aim to present two cases of COVID-19 induced atypical pneumonia, which were treated with the anti-VEGF monoclonal antibody bevacizumab.
All Keywords
【저자키워드】 acute respiratory distress syndrome, hypoxia, COVID-19 pandemic, Atypical pneumonia, bevacizumab, angiogenseis, 【초록키워드】 COVID-19, Pneumonia, acute lung injury, Novel coronavirus, global pandemic, Patient, severe pneumonia, moderate, acute respiratory distress, Atypical, proliferation, endothelial, Vascular, syndrome, VEGF, growth factor, severe inflammation, develop, treated, induce, anti-VEGF monoclonal antibody, 【제목키워드】 COVID-19,
【저자키워드】 acute respiratory distress syndrome, hypoxia, COVID-19 pandemic, Atypical pneumonia, bevacizumab, angiogenseis, 【초록키워드】 COVID-19, Pneumonia, acute lung injury, Novel coronavirus, global pandemic, Patient, severe pneumonia, moderate, acute respiratory distress, Atypical, proliferation, endothelial, Vascular, syndrome, VEGF, growth factor, severe inflammation, develop, treated, induce, anti-VEGF monoclonal antibody, 【제목키워드】 COVID-19,